Semaglutide Real-World Impact: Clinical Results and Budget Implications for Healthcare
Real-world analysis of semaglutide in T2D found significant clinical improvements alongside quantified budget impact, informing healthcare system adoption decisions.
Quick Facts
What This Study Found
Real-world semaglutide use produced significant clinical improvements in T2D, with budget impact analysis showing cost justification through prevented complications.
Key Numbers
Study period: January 2017 to December 2023. Single tertiary hospital. Patients excluded if they had prior GLP-1 RA use.
How They Did This
Real-world clinical outcomes analysis combined with budget impact modeling for semaglutide in T2D management.
Why This Research Matters
Healthcare budget holders control drug access. Demonstrating that semaglutide's clinical benefits justify its cost through prevented complications supports formulary inclusion and patient access.
The Bigger Picture
Healthcare systems globally are evaluating whether expensive GLP-1 drugs are worth the investment. Studies combining clinical and economic evidence provide the data needed for informed coverage decisions.
What This Study Doesn't Tell Us
Budget models depend on assumptions. Real-world data has confounders. Cost-effectiveness varies by healthcare system and drug pricing.
Questions This Raises
- ?At what drug price does semaglutide become budget-neutral from prevented complications?
- ?How do different healthcare systems value the real-world benefits differently?
- ?Will biosimilar semaglutide dramatically change the budget calculus?
Trust & Context
- Key Stat:
- Clinically + economically justified Real-world semaglutide benefits combined with budget impact analysis show cost justification through prevented diabetes complications
- Evidence Grade:
- Moderate evidence: real-world clinical-economic analysis combining outcomes data with budget modeling.
- Study Age:
- Published in 2025. Provides dual clinical-economic evidence for health system decision-making.
- Original Title:
- Real-world clinical and budget impact of semaglutide in type 2 diabetes mellitus in tertiary hospital in Saudi Arabia.
- Published In:
- Frontiers in clinical diabetes and healthcare, 6, 1677695 (2025)
- Database ID:
- RPEP-09822
Evidence Hierarchy
Frequently Asked Questions
Is semaglutide worth the cost for healthcare systems?
This analysis says yes — when prevented heart attacks, kidney failure, amputations, and other complications are factored in, semaglutide's clinical benefits justify its cost. The key is looking beyond the drug price to the total cost of diabetes care.
Why do insurance companies restrict GLP-1 drugs?
Insurance often focuses on immediate drug costs (,000+/month) without fully accounting for long-term savings from prevented complications. Studies like this help make the case that investing in effective drugs saves money overall.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09822APA
Al-Abdulkarim, Hana A; Alqahtani, Nawaf Salih; Al-Shraim, Mohammad; Almohammed, Omar A. (2025). Real-world clinical and budget impact of semaglutide in type 2 diabetes mellitus in tertiary hospital in Saudi Arabia.. Frontiers in clinical diabetes and healthcare, 6, 1677695. https://doi.org/10.3389/fcdhc.2025.1677695
MLA
Al-Abdulkarim, Hana A, et al. "Real-world clinical and budget impact of semaglutide in type 2 diabetes mellitus in tertiary hospital in Saudi Arabia.." Frontiers in clinical diabetes and healthcare, 2025. https://doi.org/10.3389/fcdhc.2025.1677695
RethinkPeptides
RethinkPeptides Research Database. "Real-world clinical and budget impact of semaglutide in type..." RPEP-09822. Retrieved from https://rethinkpeptides.com/research/al-abdulkarim-2025-realworld-clinical-and-budget
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.